Ellen van der Plas1, Douglas R Langbehn2, Amy L Conrad2, Timothy R Koscik2, Alexander Tereshchenko2, Eric A Epping2, Vincent A Magnotta2, Peggy C Nopoulos2. 1. From the Department of Psychiatry (E.v.d.P., T.R.K.), University of Iowa Hospitals & Clinics; and the Departments of Psychiatry (D.R.L., A.T., E.A.E., P.C.N.), Biostatistics (D.R.L., A.T.), and Radiology (V.A.M.) and Stead Family Department of Pediatrics (A.L.C.), University of Iowa, Iowa City. ellen-vanderplas@uiowa.edu. 2. From the Department of Psychiatry (E.v.d.P., T.R.K.), University of Iowa Hospitals & Clinics; and the Departments of Psychiatry (D.R.L., A.T., E.A.E., P.C.N.), Biostatistics (D.R.L., A.T.), and Radiology (V.A.M.) and Stead Family Department of Pediatrics (A.L.C.), University of Iowa, Iowa City.
Abstract
OBJECTIVE: The huntingtin gene is critical for the formation and differentiation of the CNS, which raises questions about the neurodevelopmental effect of CAG expansion mutations within this gene (mHTT) that cause Huntington disease (HD). We sought to test the hypothesis that child and adolescent carriers of mHTT exhibit different brain growth compared to peers without the mutation by conducting structural MRI in youth who are at risk for HD. We also explored whether the length of CAG expansion affects brain development. METHODS: Children and adolescents (age 6-18) with a parent or grandparent diagnosed with HD underwent MRI and blinded genetic testing to confirm the presence or absence of mHTT. Seventy-five individuals were gene-expanded (GE) and 97 individuals were gene-nonexpanded (GNE). The GE group was estimated to be on average 35 years from clinical onset. Following an accelerated longitudinal design, age-related changes in brain regions were estimated. RESULTS: Age-related striatal volume changes differed significantly between the GE and GNE groups, with initial hypertrophy and more rapid volume decline in GE. This pattern was exaggerated with CAG expansion length for CAG > 50. A similar age-dependent group difference was observed for the globus pallidus, but not in other major regions. CONCLUSION: Our results suggest that pathogenesis of HD begins with abnormal brain development. An understanding of potential neurodevelopmental features associated with mHTT may be needed for optimized implementation of preventative gene silencing therapies, such that normal aspects of neurodevelopment are preserved as neurodegeneration is forestalled.
OBJECTIVE: The huntingtin gene is critical for the formation and differentiation of the CNS, which raises questions about the neurodevelopmental effect of CAG expansion mutations within this gene (mHTT) that cause Huntington disease (HD). We sought to test the hypothesis that child and adolescent carriers of mHTT exhibit different brain growth compared to peers without the mutation by conducting structural MRI in youth who are at risk for HD. We also explored whether the length of CAG expansion affects brain development. METHODS:Children and adolescents (age 6-18) with a parent or grandparent diagnosed with HD underwent MRI and blinded genetic testing to confirm the presence or absence of mHTT. Seventy-five individuals were gene-expanded (GE) and 97 individuals were gene-nonexpanded (GNE). The GE group was estimated to be on average 35 years from clinical onset. Following an accelerated longitudinal design, age-related changes in brain regions were estimated. RESULTS: Age-related striatal volume changes differed significantly between the GE and GNE groups, with initial hypertrophy and more rapid volume decline in GE. This pattern was exaggerated with CAG expansion length for CAG > 50. A similar age-dependent group difference was observed for the globus pallidus, but not in other major regions. CONCLUSION: Our results suggest that pathogenesis of HD begins with abnormal brain development. An understanding of potential neurodevelopmental features associated with mHTT may be needed for optimized implementation of preventative gene silencing therapies, such that normal aspects of neurodevelopment are preserved as neurodegeneration is forestalled.
Authors: Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Rachael I Scahill; Gerard R Ridgway; David G Macmanus; Roger A Barker; Nick C Fox; Sarah J Tabrizi Journal: J Neurol Date: 2009-03-05 Impact factor: 4.849
Authors: Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout Journal: Lancet Neurol Date: 2010-12-02 Impact factor: 44.182
Authors: Hongzhi Wang; Jung W Suh; Sandhitsu R Das; John B Pluta; Caryne Craige; Paul A Yushkevich Journal: IEEE Trans Pattern Anal Mach Intell Date: 2012-06-26 Impact factor: 6.226
Authors: Chiara Casella; Maxime Chamberland; Pedro L Laguna; Greg D Parker; Anne E Rosser; Elizabeth Coulthard; Hugh Rickards; Samuel C Berry; Derek K Jones; Claudia Metzler-Baddeley Journal: Hum Brain Mapp Date: 2022-04-09 Impact factor: 5.399
Authors: Alexander V Tereshchenko; Jordan L Schultz; Joel E Bruss; Vincent A Magnotta; Eric A Epping; Peg C Nopoulos Journal: Neurology Date: 2020-04-07 Impact factor: 9.910
Authors: Jordan L Schultz; Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Peg C Nopoulos Journal: Ann Neurol Date: 2021-02-22 Impact factor: 10.422
Authors: Erin E Reasoner; Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Timothy R Koscik; Eric A Epping; Vincent A Magnotta; Peggy C Nopoulos Journal: J Huntingtons Dis Date: 2022
Authors: Rachel Y Cheong; Barbara Baldo; Muhammad U Sajjad; Deniz Kirik; Åsa Petersén Journal: Neuropathol Appl Neurobiol Date: 2021-01-12 Impact factor: 8.090